
Palvella Therapeutics rose 77.1% from $81.64 to $144.60, ahead of the S&P 500's +11.2%. Its worst day was Jul 20 (−21.0%), and its low came Feb 5 at $76.43.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Palvella Therapeutics shares rose 16.8%, while the S&P 500 rose 0.4%.
+16.8% · S&P 500 +0.4%
Palvella Therapeutics closed at its lowest level of the year, 6.4% below where the year started.
Story events cover the past 12 months · Times ET
−6.8% · S&P 500 −1.2%
Primary endpoint met with statistically significant improvement (mean change of +2.13; p<0.001) on the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA)Achieved statistical significance on
+37.1%, the year's best day · S&P 500 +0.7%
EPS of $-1.08 missed the $-0.93 estimate on $0.00 revenue.
+12.6% · S&P 500 +2.9%
EPS of $-1.20 missed the $-0.92 estimate on $0.00 revenue.
−13.0% · S&P 500 −0.3%
Palvella Therapeutics shares fell 21.0%, while the S&P 500 fell 0.2%.
−21.0%, the year's worst day · S&P 500 −0.2%
EPS of $-1.52 missed the $-1.16 estimate on $0.00 revenue.
+8.0% · S&P 500 +1.8%
EPS of $-1.70 beat the $-1.72 estimate on $0.00 revenue (est. $40,000.00).
−3.3% · S&P 500 −4.4%
Where it ended: a close of $144.60 on Nov 16, 2026.
Nothing in the past 12 months.
All PVLA dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PVLA and SPY from Benzinga historical bars. Not investment advice.